ArticleMethods in molecular biology (Clifton, N.J.)2026
ImmTAC: A Novel Platform of T-Cell Receptor-Based Soluble Bispecifics.
Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune mobilizing monoclonal T-cell receptors Against Cancer (ImmTAC®) molecules are innovative immunotherapies designed to harness the body's immune system to fight cancer. They consist of a soluble affinity-enhanced T-cell receptor (TCR) as the targeting arm, covalently linked to an antibody fragment specific to CD3 as the effector arm, enabling T-cell redirection and cancer cell killing. TCRs can target the intracellular antigenic landscape via recognition of peptides presented by surface localized Human Leukocyte Antigen (HLA) proteins, unlocking a choice of targets that are specific to the tumor. The ImmTAC platform has been validated in the clinic with the approval of tebentafusp in 2022 for the treatment of metastatic uveal melanoma. It is the first TCR therapeutic and first soluble bispecific targeting a solid tumor to be approved for commercial use. Here, we describe the methods to produce soluble, affinity-enhanced TCRs and high-affinity ImmTAC molecules.
Indexed as
Identifiers
42108342What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.